Free Trial

Sage Therapeutics (SAGE) Competitors

Sage Therapeutics logo
$9.20 +0.12 (+1.27%)
Closing price 02:52 PM Eastern
Extended Trading
$9.20 0.00 (0.00%)
As of 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAGE vs. BHC, GMTX, APLS, ARWR, TWST, VCEL, KNSA, NAMS, DNLI, and RXRX

Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry.

Sage Therapeutics vs. Its Competitors

Sage Therapeutics (NASDAQ:SAGE) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Bausch Health Cos has higher revenue and earnings than Sage Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$41.24M13.96-$400.67M-$5.80-1.59
Bausch Health Cos$9.63B0.27-$46M-$0.11-63.17

Sage Therapeutics currently has a consensus target price of $8.93, suggesting a potential downside of 2.85%. Bausch Health Cos has a consensus target price of $7.42, suggesting a potential upside of 6.73%. Given Bausch Health Cos' higher probable upside, analysts plainly believe Bausch Health Cos is more favorable than Sage Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sage Therapeutics
1 Sell rating(s)
15 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86

Sage Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

99.2% of Sage Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Comparatively, 8.1% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bausch Health Cos had 3 more articles in the media than Sage Therapeutics. MarketBeat recorded 7 mentions for Bausch Health Cos and 4 mentions for Sage Therapeutics. Bausch Health Cos' average media sentiment score of 0.61 beat Sage Therapeutics' score of 0.17 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sage Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bausch Health Cos
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bausch Health Cos has a net margin of -0.41% compared to Sage Therapeutics' net margin of -747.63%. Sage Therapeutics' return on equity of -68.99% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Sage Therapeutics-747.63% -68.99% -60.67%
Bausch Health Cos -0.41%-540.45%5.26%

Summary

Bausch Health Cos beats Sage Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Sage Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SAGE vs. The Competition

MetricSage TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$568.60M$2.91B$5.54B$8.95B
Dividend YieldN/A2.42%5.38%4.08%
P/E Ratio-1.5921.4227.3820.03
Price / Sales13.96285.81422.31120.16
Price / CashN/A41.9536.6357.47
Price / Book1.217.518.085.67
Net Income-$400.67M-$55.05M$3.16B$248.47M
7 Day Performance-0.92%3.16%2.12%2.90%
1 Month Performance40.81%5.92%4.43%5.75%
1 Year Performance-13.42%5.82%35.62%21.36%

Sage Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SAGE
Sage Therapeutics
3.2244 of 5 stars
$9.20
+1.3%
$8.93
-2.8%
-16.1%$568.60M$41.24M-1.59690High Trading Volume
BHC
Bausch Health Cos
3.7777 of 5 stars
$6.11
-1.1%
$7.42
+21.4%
+0.0%$2.26B$9.73B-55.5520,700
GMTX
Gemini Therapeutics
N/A$51.61
+3.0%
N/A+10.0%$2.24BN/A-51.6130High Trading Volume
APLS
Apellis Pharmaceuticals
4.5199 of 5 stars
$17.62
-0.4%
$40.05
+127.3%
-49.1%$2.21B$775.84M-9.84770Trending News
Analyst Forecast
Analyst Revision
ARWR
Arrowhead Pharmaceuticals
3.9222 of 5 stars
$15.51
+1.2%
$43.71
+181.8%
-33.0%$2.14B$3.55M-11.08400
TWST
Twist Bioscience
4.4047 of 5 stars
$35.33
+2.0%
$50.40
+42.7%
-20.4%$2.12B$347.68M-10.87990News Coverage
Positive News
VCEL
Vericel
2.9099 of 5 stars
$41.80
-0.5%
$61.14
+46.3%
-8.0%$2.10B$237.22M1,393.80300Positive News
KNSA
Kiniksa Pharmaceuticals International
3.6866 of 5 stars
$28.72
+1.0%
$38.80
+35.1%
+48.7%$2.10B$423.24M-114.88220
NAMS
NewAmsterdam Pharma
3.0531 of 5 stars
$18.21
+1.4%
$42.89
+135.5%
-6.6%$2.04B$45.56M-9.694
DNLI
Denali Therapeutics
4.534 of 5 stars
$13.62
-1.9%
$33.71
+147.5%
-31.5%$1.98B$330.53M-5.10430Positive News
RXRX
Recursion Pharmaceuticals
2.1133 of 5 stars
$4.83
-4.0%
$7.00
+44.9%
-27.2%$1.96B$58.84M-2.73400Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SAGE) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners